- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Drug Watch: Agents in late-stage development for the treatment of dermatologic disorders (January 2008) (PDF)
Drugs in development as of January 2008 for the treatment of actinic keratosis, melanoma, andpsoriasis
Key Points
Selected websites
http://www.aad.org/
American Academy of Dermatology
http://www.nlm.nih.gov/medlineplus/psoriasis.html
MedlinePlus health information on psoriasis
http://www.niams.nih.gov/
National Institute of Arthritis and Musculoskeletal and Skin Diseases
http://www.psoriasis.org/
National Psoriasis Foundation
Payers Recognize the Benefits, but Still See Weight Loss Drugs through a Cost Lens
April 12th 2024Jeffrey Casberg, M.S., R.Ph., a senior vice president of clinical pharmacy at IPD Analytics LLC, a drug intelligence firm that advises payers and pharmaceutical companies, talks about how payers are thinking about weight-loss drugs.
Drugs to Watch: Mental Health Conditions
April 11th 2024The FDA is reviewing two novel therapies: a psychedelic-assisted therapy for PTSD with a target action date of Aug. 11, 2024, and therapy for schizophrenia that does not directly block dopamine receptors with an action date of Sept. 26, 2024.
